Semax 10mg — Research Grade Neuropeptide
Semax is a synthetic heptapeptide derived from the N-terminal fragment of ACTH (adrenocorticotropic hormone, residues 4–10), originally developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Unlike its parent molecule ACTH, semax lacks adrenocortical stimulating activity. Its research interest centers on neuroprotective, neurotrophic, and cognitive effects, particularly through upregulation of brain-derived neurotrophic factor (BDNF) in neurological models. This 10mg vial provides research-grade semax at ≥99% purity, HPLC and MS/MS verified per batch.
Research Background
Semax has one of the most extensive clinical research databases among synthetic neuropeptides, supported primarily by Russian institutional publications. Published studies document its application in ischemic stroke, optic nerve atrophy, and cognitive impairment models. A key mechanism is its robust stimulation of BDNF expression — multiple rodent studies have shown 140–200% increases in hippocampal BDNF following semax administration.
For the full breakdown of semax’s BDNF mechanism, published clinical data, dosage reference, and comparison with Selank, see our Semax Amidate Research Guide. Also available as N-Acetyl Semax Amidate and N-Acetyl Semax Amidate Spray.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 10mg per vial
- Storage: −20°C, protected from light
- Sequence: Met-Glu-His-Phe-Pro-Gly-Pro
- Molecular Weight: 813.9 Da
Certificate of Analysis
All semax vials are third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
